pegylated liposomal doxorubicin / Generic mfg. - LARVOL DELTA

A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34). (ASCO 2026) - P2 | " Randomized phase II trial comparing 6 cycles of carboplatin AUC5+MIRV 6 mg/kg AIBW every 3 weeks followed by MIRV versus 6 cycles of carboplatin combined with either paclitaxel, gemcitabine or pegylated liposomal doxorubicin followed by maintenance PARP inhibitor (PARPi) if applicable...Of them, 112/145 (77.2%) patients had received prior bevacizumab and 97/145 (66.9%) had prior PARPi, 15.2% were BRCAmut... MIROVA/AGO-OVAR 2.34 is the first randomized trial evaluating the activity and safety of the combination of carboplatin with an antibody-drug conjugate in the setting of platinum-eligible relapsed ovarian cancer. The primary endpoint regarding improvement of PFS was not met. Further analysis will be presented."

Clinical • P2 data • Oncology • Ovarian Cancer • Solid Tumor • BRCA • FOLR1

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. (PubMed, J Clin Oncol) - P3 | "Two hundred sixty-six patients were randomly assigned 2:1 to olaparib tablets (300 mg twice daily; n = 178) or physician's choice of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan; n = 88). BRCA reversion mutations might have contributed to this finding. No patient randomly assigned to olaparib with a BRCA reversion mutation detected at baseline (6 of 170 [3.5%]) achieved an objective tumor response."

Journal • P3 data • Oncology • Ovarian Cancer • Solid Tumor • BRCA

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. (PubMed, Nat Med) - P2 | "Patients received pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide in combination with atezolizumab (atezo-chemo; n = 40) or placebo (placebo-chemo; n = 28). The progression-free proportion after 15 months was 14.7% (5/34; 95% CI 6.4-30.1%) in the atezo-chemo arm versus 0% in the placebo-chemo arm. The addition of atezolizumab to PLD/cyclophosphamide was tolerable with an indication of clinical benefit, and the findings warrant further investigation of PD1/PD-L1 blockers in combination with immunomodulatory chemotherapy."

Clinical • Journal • P2b data • Breast Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • Triple Negative Breast Cancer

A randomized phase II trial of mirvetuximab soravtansine, in folate receptor alpha (FR?) high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34) (ESMO-Gynae 2026) - P2 | "Methods Randomized phase II trial comparing 6 cycles of carboplatin combined with either paclitaxel, gemcitabine or pegylated liposomal doxorubicin followed by maintenance PARP inhibitor (PARPi) if applicable (arm A) versus 6 cycles of carboplatin AUC5+MIRV 6 mg/kg AIBW every 3 weeks followed by MIRV (arm B)...Of them, 112/145 (77.2%) patients had received prior bevacizumab and 97/145 (66.9%) had prior PARPi, 14.5% were BRCAmut...The combination of carboplatin/mirvetuximab soravtansine is feasible and shows high response rates, but this did not result in a longer median PFS, which was the primary endpoint. No new safety signals have been observed."

Clinical • P2 data • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • BRCA • FOLR1

Biopsy-proven kidney-limited thrombotic microangiopathy associated with bevacizumab and pegylated liposomal doxorubicin: a case with a biphasic clinical course. (PubMed, CEN Case Rep) - "Following discontinuation of PLD, kidney function improved markedly with complete resolution of proteinuria. This case highlights the importance of kidney biopsy and careful clinicopathological correlation in diagnosing drug-induced kidney-limited TMA."

Journal • Hematological Disorders • Nephrology • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Renal Disease • Thrombocytopenia

PHASE 2 STUDY OF UBAMATAMAB ALONE OR IN COMBINATION WITH ADDITIONAL AGENTS IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: TRIAL IN PROGRESS (IGCS 2026) - P2 | "Combination arms include ubamatamab + standard doses of bevacizumab (Arm B), triple immunotherapy (ubamatamab + cemiplimab + fianlimab; Arm C), and ubamatamab + pegylated liposomal doxorubicin (Arm D). Patients will receive sarilumab prophylaxis to mitigate CRS risk...Primary completion is December 2028. With limited immunotherapy options in PROC, ubamatamab may offer a novel approach."

Clinical • Combination therapy • P2 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Nab-paclitaxel plus pegylated liposomal doxorubicin in advanced or unresectable malignant vascular tumors: results from a phase II study (ESMO 2026) - No abstract available

Metastases • P2 data • Oncology • Sarcoma • Solid Tumor

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. (PubMed, N Engl J Med) - P3 | "Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with MIRV showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response. (Funded by ImmunoGen; MIRASOL ClinicalTrials.gov number, NCT04209855.)."

Journal • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • FOLR1

Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial. (PubMed, Clin Cancer Res) - "In PROC patients with prior bevacizumab, all experimental arms failed to reach the primary objective of improving PFS compared with SOC."

Journal • Monotherapy • P2 data • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005. (PubMed, J Clin Oncol) - "The cediranib-containing arms demonstrated clinical activity on the basis of PFS but were not superior compared with SOC."

Journal • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer (ESMO 2022) - P2b | "Arm A patients received only chemotherapy, i.e. pegylated liposomal doxorubicin (PLD; 20mg/m 2 every 2 nd week) + cyclophosphamide (cyclo; 50mg/day, 2/4 weeks). Patients receiving ipi/nivo had more adverse events, but the toxicity was manageable. Biomarker analyses will be important to determine if further studies on selected subgroups are warranted."

Clinical • IO biomarker • P2b data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PD-L1 • TMB

Safety and efficacy results in patients who received dose modifications in the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial of mirvetuximab soravtansine vs investigator's choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha expression (ESMO-GC 2024) - " 453 PROC pts with high FRα expression (VENTANA FOLR1 [FOLR1-2.1] RxDx Assay) with 1-3 prior therapies were randomized 1:1 to MIRV 6 mg/kg, adjusted ideal body weight, Day 1 of a 21-day cycle or ICC: paclitaxel, pegylated liposomal doxorubicin, or topotecan...In the MIRV arm, 36% had prior bevacizumab vs. 45% in the ICC arm, and 55% had prior PARPi vs 59% in the ICC... Dose modifications occurred at similar rates in both treatment arms. MIRV demonstrated a longer PFS, OS, and higher ORR vs ICC in patients with dose modifications. The efficacy data and the well-characterized safety profile support MIRV as the standard of care for pts with FRα positive PROC."

Clinical • P3 data • Gastrointestinal Disorder • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

Intra-arterial chemotherapy for relapsing malignant gliomas. (EANO 2026) - "Tumour progression often occurs during or after standard first-line therapy comprised of radiotherapy with concomitant and adjuvant temozolomide...The following chemotherapeutic agents were used: carboplatin, melphalan, methotrexate, Caelyx, carboplatin + melphalan, carboplatin + methotrexate, carboplatin + etoposide phosphate or melphalan + methotrexate... Compared with published clinical trial results, our series data indicate that IAC is a promising treatment modality for relapsing malignant gliomas. We will gather more data and perform uni- and multivariate analyses. Moreover, we have initiated a randomized clinical trial to test the combination of carboplatin + etoposide phosphate and carboplatin + Caelyx in the treatment of relapsing GBM."

Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor

A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES). (ASCO 2024) - P3 | "After the investigators chose chemotherapy (CT) (weekly paclitaxel 80 mg/ m 2 d1, 8, 15 & 22 q4w, pegylated liposomal doxorubicin 40 mg/m 2 d1 q4w or topotecan 4 mg/m 2 d1, 8 & 15 q4w), patients were randomly assigned (2:1) to either Suvemcitug (1.5 mg/kg q2w) or placebo combine with CT until progression or unacceptable toxicity. To the best of our knowledge, this is the first double-blinded phase III study demonstrated promising antitumor activity of anti-angiogenic agent in patients with PROC. The improvement in PFS, ORR and DCR gained by adding Suvemcitug to single-agent CT was observed with no new safety concern."

Clinical • Late-breaking abstract • P3 data • Oncology • Ovarian Cancer • Solid Tumor

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study. (ASCO 2024) - P3 | "Background: Paclitaxel or pegylated liposomal doxorubicin (PLD) in combination with bevacizumab (bev) are standard treatment options in patients with relapsed ovarian cancer not candidates for platinum, but responses are usually short-lived. The addition of atezo to chemo plus bev did not significantly improve OS or PFS in pts. with recurrent ovarian cancer who are no candidates for platinum. Safety was within the expected range."

Clinical • Combination therapy • Late-breaking abstract • Oncology • Ovarian Cancer • Solid Tumor • PD-L1

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. (PubMed, J Clin Oncol) - "Trabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy."

Journal • P3 data • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

19-C-0103: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (clinicaltrials.gov) - P2 | N=48 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2028 ➔ Dec 2029 | Trial primary completion date: Jul 2027 ➔ Dec 2028

Trial completion date • Trial primary completion date • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Secondary Central Nervous System Lymphoma

Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. (PubMed, Eur J Cancer) - "No new safety signals were identified. TTFields+PTX did not significantly improve OS compared with PTX in the intent-to-treat population. An exploratory post-hoc analysis suggests a potentially favorable benefit-risk profile for TTFields therapy in PLD-naive patients."

Journal • P3 data • Oncology • Ovarian Cancer • Solid Tumor

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "This randomized clinical trial found that treatment with apatinib plus PLD showed promising efficacy and manageable toxic effects in patients with PROC and may be a new alternative treatment option in this setting. Clinicaltrials.gov Identifier: NCT04348032."

Clinical • Journal • Cardiovascular • Hypertension • Oncology • Ovarian Cancer • Solid Tumor

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. (ASCO 2023) - P3 | " 453 PROC pts with high FRα expression (Roche FOLR1 Assay) with 1-3 priors were randomized 1:1 to MIRV 6 mg/kg, adjusted ideal body weight, Day 1 of a 21-day cycle or IC: paclitaxel, pegylated liposomal doxorubicin, or topotecan. MIRV is the first treatment to demonstrate a PFS and OS benefit in PROC compared to IC. The efficacy data, along with the well-characterized safety profile, position MIRV as a new, standard of care for pts with FRα positive PROC. Clinical trial information: NCT04209855."

Late-breaking abstract • Metastases • P3 data • Fallopian Tube Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor • FOLR1

Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial (ESMO 2023) - P3 | "Pts were stratified by carboplatin (carbo) doublet (paclitaxel, gemcitabine or pegylated liposomal doxorubicin [PLD]), TFIp (6–12 vs >12 mo), BRCA status (mutated vs non-mutated) and PD-L1 status (PD-L1-expressing immune cells on 12 mo, 11% prior PARPi after front-line CT, 54% prior bevacizumab); most (71%) received carbo–PLD and 74% began maintenance...Table: LBA37 PFS Pbo + CT → pbo + niraparib (n=209) Atezo + CT → atezo + niraparib (n=208) All pts Events, n (%) 174 (83) 170 (82) Hazard ratio (95% CI) 0.89 (0.71–1.10); p=0.28 Median, mo (95% CI) 10.1 (9.2–11.2) 11.2 (10.1–12.1) PD-L1-positive subgroup Events, n/N (%) 60/73 (82) 61/76 (80) Hazard ratio (95% CI) 0.87 (0.61–1.25)a Median, mo (95% CI) 11.1 (9.7–12.7) 12.8 (10.2–15.4) PD-L1-negative subgroup Events, n/N (%) 92/112 (82) 97/117 (83) Hazard ratio (95% CI) 0.93 (0.70–1.24)a Median, mo (95% CI) 9.2 (8.3–11.1) 10.5 (9.2–11.8) aUnadjusted estimate. Conclusions Combining atezo with CT and maintenance..."

Clinical • IO biomarker • Late-breaking abstract • P3 data • Oncology • Ovarian Cancer • Solid Tumor • BRCA • PD-L1

FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN'S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) (IGCS 2025) - P2/3 | " This international phase 2/3 trial randomly assigned (1:1) patients with recurrent LGSOC to receive either oral trametinib 2 mg once daily (n=130) or one of five SoC treatment options (n=130): intravenous paclitaxel 80 mg/m² by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40–50 mg/m² once every 4 weeks; intravenous topotecan 4 mg/m² on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. At the time of the final analysis, 29 (22.3%) patients in the trametinib arm and 15 (11.5%) patients in the SoC arm remained alive. The median OS was 36.4 months in the trametinib arm versus 29.8 months in the SoC arm (HR 0.68; 95% CI 0.49-0.94; p=0.018, 1-sided), despite the fact that 72% of patients in the SoC arm crossed over to trametinib following progression. In the 93 SoC patients who crossed over to trametinib the median PFS..."

Clinical • Late-breaking abstract • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Phase 1b study of igrelimogene litadenorepvec plus pembrolizumab and pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: preliminary safety and efficacy results (ESMO 2026) - No abstract available

Clinical • P1 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23). (ASCO 2022) - P2 | " In this open-label, phase III, randomized trial, we assigned recurrent OC patients harboring BRCA 1/2 mutations or with BRCAness phenotype (defined as patients who had received and responded to at least 2 previous platinum-based treatments) to receive trabectedin 1.3 mg/mq q 21d or physician’s choice chemotherapy (among carboplatin, gemcitabine, weekly paclitaxel, pegylated liposomal doxorubicine or topotecan). Trabectedin as single agent does not improve survival outcomes when compared to standard chemotherapy in BRCA mut and BRCAness phenotype OC patients."

Clinical • Late-breaking abstract • P3 data • Fallopian Tube Cancer • Oncology • Ovarian Cancer • BRCA • BRCA1 • BRCA2

PEGylated Liposomal Nanocarriers in Cancer Therapy: Emerging Strategies and Clinical Prospects. (PubMed, Recent Adv Drug Deliv Formul) - "PEGylated liposomes are a pharmaceutically established and maturing nanomedicine technology in oncology. Their further advancement toward multifunctional, personalized, and immunologically safer designs promises to deliver cancer therapeutics."

Journal • Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor